Alzheimer's Treatment Side Effects: Recognizing Problems and Getting the Right Help

A person starts treatment for Alzheimer's disease and then eats less, sleeps through lunch, or becomes unsteady. Is the medicine responsible, is dementia progressing, or has a separate illness developed? These explanations can overlap. The timing of a symptom, recent prescription changes, actual doses taken, and the person's wider health history all matter. Finding a symptom in a medication leaflet does not establish its cause in an individual patient.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Sudden facial weakness, loss of strength on one side, difficulty speaking, a seizure, markedly reduced consciousness, or a severe headache with new neurological changes require emergency assessment. For someone receiving an anti-amyloid antibody, tell the emergency team the medicine's name and the date of the latest dose. Amyloid-related imaging abnormalities, or ARIA, can sometimes resemble a stroke. A genuine stroke is also possible; the family should not try to distinguish these conditions at home. FDA information on Kisunla
Lecanemab and donanemab carry risks of ARIA, including swelling and bleeding-related changes seen on brain imaging. Some abnormalities cause no obvious symptoms. A person looking well between appointments therefore does not remove the need for scheduled imaging. APOE ε4 homozygosity increases risk, but a genetic result cannot predict with certainty whether a particular patient will develop ARIA. 2026 Alzheimer's Association ARIA workgroup update
A useful adverse-event note identifies the medicine and strength, actual administration time, recent changes, symptom onset, duration, effect on activities, and action already taken. If several people provide care, maintain one shared administration record. An empty compartment in a pill organizer does not by itself prove that its contents were taken correctly.

Quick answer

Full guide

Treatment should support daily life as well as cognitive goals. Persistent vomiting, recurrent falls, or marked sedation deserve attention even if a test score appears stable. Conversely, one mild symptom does not automatically mean that every treatment option must be abandoned. A clear account of what changed helps the prescriber decide whether to investigate another cause, modify treatment, or continue with closer observation. NIA treatment overview

Recognize situations that cannot wait for a routine appointment

Sudden facial weakness, loss of strength on one side, difficulty speaking, a seizure, markedly reduced consciousness, or a severe headache with new neurological changes require emergency assessment. For someone receiving an anti-amyloid antibody, tell the emergency team the medicine's name and the date of the latest dose. Amyloid-related imaging abnormalities, or ARIA, can sometimes resemble a stroke. A genuine stroke is also possible; the family should not try to distinguish these conditions at home. FDA information on Kisunla

Difficulty breathing, swelling of the mouth or throat, collapse, vomiting blood, or black tarry stools also call for urgent medical help. Use the local emergency number; in mainland China, ambulance services can be reached through 120. Bring medication containers or clear photographs if readily available, but do not delay care to complete paperwork. Saying that a person takes a “memory medicine” is less useful than identifying its actual ingredient. Donepezil patient information

Appetite and stomach symptoms need a timeline

Cholinesterase inhibitors such as donepezil, galantamine, and rivastigmine can cause gastrointestinal symptoms. A recent start or dose increase may be relevant. Write down when the prescription changed, whether nausea or diarrhea followed, and how much the person is managing to eat and drink. This gives the clinician more useful information than a general statement that the medicine “does not agree with them.”

Weight loss should not be dismissed as an inevitable consequence of age. Dental pain, swallowing difficulty, depression, constipation, and other illnesses can affect intake too. To follow a trend, use the same scale under similar conditions instead of comparing unrelated measurements. If a person cannot keep fluids down, becomes unusually weak, or passes much less urine, seek medical advice promptly. Adding supplements without investigating the problem can leave its cause untreated. NIA guidance on caring for cognitive impairment

The practical question for a review is not simply whether nausea is a recognized adverse effect. It is whether the current treatment can be used with an acceptable burden for this person. The answer may depend on their weight, other conditions, previous responses, and the pace of dose adjustment. A caregiver should report those details rather than quietly tolerating a worsening pattern until the next scheduled prescription renewal.

A skin patch is still a systemic medicine

Rivastigmine delivered through a patch can affect the whole body. During a caregiving handover, confirm that the previous patch was removed before a new one was applied. Two relatives can unintentionally give duplicate treatment when each assumes the other has not done so. Do not cut patches or use extra patches to compensate for a missed application. Direct heat from a heating pad or similar source should be avoided over the patch.

Record the location and appearance of a skin reaction. Redness spreading beyond the patch area, blistering, or worsening irritation needs professional advice. A dated photograph may help explain how it evolved. Contact the prescriber before restarting after several days without treatment; returning directly to a previous strength may be inappropriate. Nausea, fainting, or a slow heartbeat must still be assessed as possible systemic problems, even when the medicine was not swallowed. Rivastigmine patch information

Dizziness or sleepiness can be mistaken for disease progression

Memantine can be associated with dizziness, constipation, sleepiness, or changes in mental state. A review should establish the formulation, actual use, kidney history, and other medicines. Include nonprescription cough products: dextromethorphan is an ingredient that needs to be considered when checking interactions with memantine. Memantine patient information

Describe what happens in ordinary activities. “Held the wall while walking to the bathroom after getting up” or “fell asleep repeatedly during lunch” is more informative than “seems worse.” After a fall, clinicians also need to consider injury, not only its possible medication trigger. A person may have difficulty recalling that their head struck a surface or explaining a painful movement.

Do not repeatedly stop and restart medicine at home to prove causation. That can create additional risk and make the sequence harder to interpret. Tell the clinician what has already been missed, duplicated, stopped, or restarted. Accurate reporting is more valuable than presenting an apparently perfect dosing history that does not match what happened.

MRI monitoring is part of anti-amyloid treatment

Lecanemab and donanemab carry risks of ARIA, including swelling and bleeding-related changes seen on brain imaging. Some abnormalities cause no obvious symptoms. A person looking well between appointments therefore does not remove the need for scheduled imaging. APOE ε4 homozygosity increases risk, but a genetic result cannot predict with certainty whether a particular patient will develop ARIA. 2026 Alzheimer's Association ARIA workgroup update

Monitoring schedules differ. The July 2026 US Leqembi label specifies a baseline MRI and scans after approximately 1, 2, 3, and 6 months of treatment. The cited US Kisunla label calls for MRI before the second, third, fourth, and seventh infusions. A Chinese treating institution should provide a calendar based on the applicable local label and its clinical protocol. Ask who reviews each scan and how permission to proceed with the next dose is communicated. Current Leqembi label, Kisunla label

If imaging identifies ARIA, decisions about continuation, interruption, or discontinuation depend on the imaging findings, symptoms, and clinical circumstances. Another patient's online account is not a treatment rule. Provide the full history of anticoagulants and antiplatelet medicines; do not stop a cardiovascular prescription independently to try to qualify for an antibody.

For international care, clarify whether the home hospital can provide the required MRI sequences and transfer the original images. An overseas report saying “no acute abnormality” may not answer every question the prescribing team needs resolved. A workable monitoring arrangement requires both access to imaging and a clinician responsible for acting on it.

Infusion reactions and injection reactions need distinct instructions

During an infusion, report chills, rash, chest discomfort, or breathing changes to the staff immediately. Symptoms beginning after departure should be handled according to the center's written contact instructions. A previous uneventful treatment does not guarantee that every later dose will be uneventful. Whether precautions or pretreatment should change belongs in the clinical review of the reaction.

A September 3, 2026 announcement reported Chinese approval of subcutaneous lecanemab for treatment initiation. That announcement does not establish stock at every hospital. Subcutaneous administration also does not remove systemic risks or MRI requirements. Before any home use, the family needs product-specific training, a plan for injection or device problems, and instructions about adverse reactions. An online demonstration alone cannot establish that a patient and caregiver are ready to administer treatment. Chinese approval announcement

Less agitation is not the same as excessive sedation

If shouting decreases but the person sleeps through most of the day, struggles to swallow, or cannot stand safely, report the full change. Brexpiprazole has a US indication for agitation associated with dementia due to Alzheimer's disease, but its label retains a boxed warning about increased mortality in elderly patients with dementia-related psychosis. Falls, postural hypotension, and metabolic effects also require consideration. An approved indication does not make the medicine suitable for every behavioral change. Rexulti labeling

Auvelity received a US Alzheimer's dementia agitation indication in April 2026 and has a different safety profile. Seizure disorder is a contraindication. Blood pressure, low sodium, serotonin syndrome, and duplicate ingredients are among the issues for prescribing review. It is not an as-needed response to each episode of agitation and cannot be replaced with ordinary cough medicine. US authorization does not establish Chinese authorization or supply. FDA announcement, 2026 Auvelity label

Pain, delirium, frightening surroundings, and communication difficulties still need attention. NICE recommends the lowest effective antipsychotic dose for the shortest feasible period, with reassessment at least every six weeks. This is a review interval, not a reason to wait six weeks after a serious adverse change. NICE NG97 recommendations

Keep the record short enough to use

A useful adverse-event note identifies the medicine and strength, actual administration time, recent changes, symptom onset, duration, effect on activities, and action already taken. If several people provide care, maintain one shared administration record. An empty compartment in a pill organizer does not by itself prove that its contents were taken correctly.

Before treatment in China or a return home, transfer previous reactions, allergy information, the clinical assessment of each event, reasons for any treatment interruption, and relevant original MRI files. Identify who will make the next prescribing decision. A certificate saying “treatment completed” cannot replace this information. Even when the cause of a reaction remains uncertain, preserving the facts allows the next clinician to assess it without reconstructing the entire history from memory.